NCT01946074 - A Study of ABT-165 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

August 8, 2013

Primary Completion Date

September 28, 2022

Study Completion Date

September 28, 2022

Conditions

Advanced Solid Tumors

Interventions

DRUG

paclitaxel

Paclitaxel will be administered by intravenous infusion.

DRUG

FOLFIRI

5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.

DRUG

ABT-165

ABT-165 will be administered by intravenous infusion at escalating dose levels.

DRUG

ABBV-181

ABBV-181 will be administered by intravenous infusion.

Trial Locations (10)

Horizon Oncology Research Center /ID# 138022, Lafayette

Illinois Cancer Care, PC /ID# 151970, Peoria

Mary Crowley Cancer Research /ID# 123757, Dallas

University of California, Los Angeles /ID# 141389, Los Angeles

University of California, Davis Comprehensive Cancer Center /ID# 141164, Sacramento

HonorHealth Research Institute - Pima /ID# 105677, Scottsdale

Scottsdale Healthcare /ID# 105678, Scottsdale

Stanford University School of Med /ID# 123758, Stanford

Duke Cancer Center /ID# 105679, Durham

Tennessee Oncology-Nashville Centennial /ID# 143280, Nashville